We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.87B
AUM Growth
+$772M
Cap. Flow
-$1.35B
Cap. Flow %
-17.14%
Top 10 Hldgs %
73.35%
Holding
114
New
19
Increased
20
Reduced
44
Closed
6

Top Buys

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$93M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$34.7M
3
ACOR
Acorda Therapeutics
ACOR
+$33.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29M
5
XNPT
XENOPORT, INC.
XNPT
+$18.1M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$41.4M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$35.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$25.4M
4
HALO icon
Halozyme
HALO
+$8.89M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 48.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYAX
26
DELISTED
DYAX CORPORATION
DYAX
$22.7M 0.29%
2,531,766
+505,229
+25% +$4.59M
AVNR
27
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$21.3M 0.27%
5,790,139
+361,548
+7% +$1.38M
XNPT
28
DELISTED
XENOPORT, INC.
XNPT
$20.9M 0.27%
4,034,112
+3,000,000
+290% +$18.1M
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.2M 0.23%
4,449,797
+249,797
+6% +$1.28M
NGNE icon
30
Neurogene
NGNE
$773M
$15.4M 0.2%
+60,593
New +$15.6M
TGTX icon
31
TG Therapeutics
TGTX
$8.31B
$14.9M 0.19%
2,160,965
-38,691
-2% -$229K
KYTH
32
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$12.4M 0.16%
311,255
-1,936
-0.6% -$86.6K
ARWR icon
33
Arrowhead Research
ARWR
$12.3B
$12M 0.15%
732,062
-2,357,938
-76% -$41.4M
INSM icon
34
Insmed
INSM
$27.5B
$10.5M 0.13%
554,050
-242,328
-30% -$4.61M
ABUS icon
35
Arbutus Biopharma
ABUS
$1.03B
$10.4M 0.13%
484,156
-15,844
-3% -$285K
SGMO
36
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.45M 0.12%
522,764
+98,456
+23% +$1.9M
SGYP
37
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$9.34M 0.12%
1,758,271
-886,516
-34% -$4.97M
OMER icon
38
Omeros
OMER
$1.39B
$9.1M 0.12%
753,804
+145,400
+24% +$1.79M
PRTA icon
39
Prothena Corp
PRTA
$485M
$8.82M 0.11%
230,142
-106,776
-32% -$3.44M
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$8.69M 0.11%
11,069
-158
-1% -$128K
QLTI
41
DELISTED
QLT Inc
QLTI
$8.54M 0.11%
1,535,863
– –
WINT
42
DELISTED
Windtree Therapeutics Inc
WINT
$7.85M 0.1%
260,866
-4,750
-2% -$160K
AGIO icon
43
Agios Pharmaceuticals
AGIO
$1.98B
$7.83M 0.1%
199,893
-5,857
-3% -$196K
GALT icon
44
Galectin Therapeutics
GALT
$371M
$7.66M 0.1%
500,000
+399,400
+397% +$5.69M
INFI
45
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.42M 0.09%
+624,050
New +$8.37M
NBIX icon
46
Neurocrine Biosciences
NBIX
$15.5B
$7.21M 0.09%
+447,874
New +$7.66M
STML
47
DELISTED
Stemline Therapeutics, Inc.
STML
$6.89M 0.09%
338,671
-336,371
-50% -$8.16M
AMBI
48
DELISTED
Ambit Biosciences Corp
AMBI
$6.82M 0.09%
747,954
– –
VXRT
49
DELISTED
Vaxart
VXRT
$6.76M 0.09%
100,628
-2,110
-2% -$130K
ARRY
50
DELISTED
Array Biopharma Inc
ARRY
$6.74M 0.09%
1,433,797
-66,203
-4% -$333K
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2014 Portfolio in Review

As of Q1 2014, Julian Baker held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Julian Baker withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier.

Against the trend, Julian Baker opened a new position in Acorda Therapeutics worth $37.9M.

  • Julian Baker's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
  • Julian Baker added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
  • Julian Baker's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
  • Julian Baker fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
  • Julian Baker's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
  • Julian Baker opened 19 new positions and closed 6 in Q1 2014.
  • Julian Baker's portfolio value rose 11% quarter-over-quarter to $7.87B.

Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.